EP Patent

EP4071151A1 — Syringe containing nmtx bromide

Assigned to Wyeth LLC · Expires 2022-10-12 · 4y expired

What this patent protects

The present invention provides a use of a prefilled syringe comprising a liquid composition comprising N-methylnaltrexone bromide and that is substantially free from tungsten, for storing the N-methylnaltrexone, thus protecting the N-methylnaltrexone against degradation during st…

USPTO Abstract

The present invention provides a use of a prefilled syringe comprising a liquid composition comprising N-methylnaltrexone bromide and that is substantially free from tungsten, for storing the N-methylnaltrexone, thus protecting the N-methylnaltrexone against degradation during storageto a compound of formula II-1:

Drugs covered by this patent

Patent Metadata

Patent number
EP4071151A1
Jurisdiction
EP
Classification
—
Expires
2022-10-12
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.